Stereotactic radiosurgery for locoregional leptomeningeal metastasis: defining a role for focal treatment - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Stereotactic Radiosurgery for Localized Leptomeningeal Metastases: Establishing a Role for Focal Therapy

  • By

  • Bardia Hajikarimloo

  • Salem M. Tos

  • Jason P. Sheehan

  • November 20, 2026

Share

Clinical Scorecard: Stereotactic Radiosurgery for Localized Leptomeningeal Metastases: Establishing a Role for Focal Therapy

At a Glance

CategoryDetail
ConditionNodular or localized leptomeningeal metastases, distinguished radiographically from linear or mixed leptomeningeal disease and from postoperative dural seeding.
Key MechanismsDiscrete nodules may reflect tumor-cell spillage into CSF-contacting spaces during resection, but this proposed mechanism is unproven; CSF dissemination may also occur beyond visible targets.
Target PopulationSelected patients with discrete, safely treatable nodular deposits, preserved functional status, and a meaningful prospect of benefiting from ongoing oncologic therapy.
Care SettingMultidisciplinary CNS oncology care using neurologic assessment, contrast-enhanced brain and spine MRI, and CSF evaluation when appropriate; focal radiotherapy may be considered within multimodality treatment.

Key Highlights

  • Contrast-enhanced MRI is the reference standard for characterizing leptomeningeal disease patterns; imaging classification does not establish biologic confinement.
  • EANO-ESMO guidance supports focal stereotactic irradiation for appropriately selected nodular disease.
  • Small clinical series report feasibility and responses of treated deposits, but do not establish a definitive survival benefit from SRS.
  • Distant leptomeningeal progression remains possible after focal treatment; untreated meningeal sites may require broader or systemic treatment.
  • Evidence is insufficient to define an optimal stereotactic regimen specifically for localized leptomeningeal metastasis.

Guideline-Based Recommendations

Diagnosis

  • Assess disease pattern with contrast-enhanced MRI, the reference standard, distinguishing linear, nodular, and mixed presentations.
  • Use an integrated assessment including neurologic examination, contrast-enhanced MRI of the brain and spine, and CSF evaluation when appropriate.
  • Do not interpret negative CSF cytology as confirmation that disease is confined; positive cytology does not automatically preclude treatment of a symptomatic nodule.

Management

  • Consider focal stereotactic irradiation for appropriately selected nodular disease; the EANO-ESMO framework supports this approach.
  • Consider SRS within a broader multimodality strategy, including CNS-penetrant systemic therapy when appropriate.
  • Reconsider focal treatment as the principal approach when there is extensive linear enhancement, rapidly increasing nodules, or neurologic decline disproportionate to the visible target.
  • Account for target delineation, prior radiation-dose overlap, and the implications of marginal progression in treatment planning.

Monitoring & Follow-up

  • Assess for distant leptomeningeal progression after SRS; distant disease occurred in seven of 16 patients in one reported series.
  • Report single-fraction SRS, hypofractionated SRS, and fractionated stereotactic radiotherapy as distinct interventions.

Risks

  • Focal treatment may control an irradiated deposit while untreated meningeal sites remain vulnerable to progression.
  • Available comparative findings do not establish therapeutic equivalence between focal radiotherapy and WBRT; treatment groups may differ in disease distribution, functional status, or systemic treatment options.
  • Meningeal lesions may be thin or irregular and near previously irradiated tissue or critical neural structures.

Patient & Prescribing Data

Patients with discrete nodular leptomeningeal deposits that are amenable to safe treatment may be considered; proposed selection principles are not validated eligibility criteria.

SRS may control a targeted deposit, but evidence does not establish a survival benefit or an optimal regimen. Distant leptomeningeal progression can occur, and focal therapy may be combined with CNS-penetrant systemic treatment.

Clinical Best Practices

  • Distinguish genuine leptomeningeal involvement from postoperative pachymeningeal seeding and avoid inferring confinement from proximity to a surgical cavity.
  • Interpret MRI pattern alongside neurologic findings, brain and spine imaging, and CSF evaluation when appropriate.
  • Consider whether a nodule threatens a defined neurologic function or represents limited progression amid otherwise effective treatment.
  • Document prior irradiation and explicitly assess target definition, dose overlap, and marginal progression risk.
  • Avoid treating stereotactic regimens as interchangeable; the source reports insufficient evidence to establish a preferred regimen.

Related Resources & Content

    Original Source(s)

    Related Content